CalciMedica, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
CALC$1.37-9.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities: | ||
| Net loss | $(18,802) | $(9,442) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 2,349 | 1,681 |
| Depreciation | 41 | 44 |
| Change in the fair value of warrant liability | (177) | (7,790) |
| Change in the fair value of promissory note | (23) | — |
| Promissory note issuance costs | 336 | — |
| Transaction costs associated with warrants | — | 776 |
| Accretion of discount on short-term investments | (307) | (492) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses, other current and non-current assets | 281 | (705) |
| Accounts payable | (884) | 117 |
| Accrued expenses and other liabilities | 860 | (363) |
| Net cash used in operating activities | (16,326) | (16,174) |
| Investing activities: | ||
| Purchase of investments | (15,420) | (18,837) |
| Maturity of investments | 17,845 | 19,587 |
| Purchase of property and equipment | (22) | (6) |
| Net cash provided by investing activities | 2,403 | 744 |
| Financing activities: | ||
| Proceeds from issuance of common stock, net of issuance costs | 8 | 18,983 |
| Proceeds from exercise of stock options | 25 | 20 |
| Proceeds from issuance of promissory note, net | 9,664 | — |
| Proceeds from issuance of common stock from ATM Facility, net of issuance costs | 1,761 | 49 |
| Net cash provided by financing activities | 11,458 | 19,052 |
| Net (decrease) increase in cash and cash equivalents | (2,465) | 3,622 |
| Cash and cash equivalents at beginning of period | 7,935 | 5,530 |
| Cash and cash equivalents at end of period | $5,470 | $9,152 |
| Supplemental cash flow information: | ||
| Stock issuance costs in accounts payable | $28 | $— |
| Equipment purchases included in accounts payable | $4 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.